Business Context and Reporting Period
Company: MEI Pharma, Inc. (Note: Request metadata listed "Lite Strategy, Inc.", but the filing text identifies the registrant as MEI Pharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2012
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) for a private placement transaction.
Key Financial Metrics and Transaction Details
- Aggregate Purchase Price: $27,500,000
- Securities Issued: 55,000,000 Units
- Unit Composition: 1 share of Common Stock + Warrants to acquire 0.70 shares of Common Stock.
- Warrant Exercise Price: $0.52 per share.
- Total Warrant Shares: 38,500,000 shares.
- Use of Proceeds: Funding a Phase II clinical study of Pracinostat in Myelodysplastic Syndrome, general corporate purposes, and working capital.
- Transaction Expenses: Company agreed to pay up to $100,000 of expenses incurred by Vivo and New Leaf.
Note: This filing does not provide historical revenue, profit, cash flow, or debt metrics. It is a transaction report, not a financial statement.
Material Changes and Conditions
- Stockholder Approval: The transaction is subject to stockholder approval. The majority stockholder, Novogen Limited, provided written consent on November 5, 2012, effective 20 days after mailing an information statement to other stockholders.
- Reverse Stock Split: The Company intends to effect a 1-for-10 reverse stock split prior to Closing.
- Board Governance Changes: Upon Closing, the Board of Directors will increase from six to seven members. The Company must hold a stockholder meeting within three months of Closing to eliminate the classified Board structure (moving to annual elections) and amend by-laws regarding indemnification.
- Investor Rights: Purchasers (Vivo and New Leaf) gain rights to propose board candidates and, subject to ownership thresholds, have a director elected as Chairman of the Board.
Outlook, Risks, and Covenants
- Right of First Refusal: Purchasers holding at least 3,000,000 shares (post-split) have a right to purchase their pro rata portion of any subsequent equity financing prior to December 31, 2013, subject to prior obligations to 2011 PIPE Investors.
- No-Shop Provision: The Company is prohibited from soliciting or entering into agreements regarding acquisitions, mergers, or asset sales with third parties until the earlier of Closing or termination of the agreement.
- Registration Rights: The Company must file an Initial Registration Statement within 30 days of Closing. Failure to file or maintain effectiveness triggers liquidated damages of 1% per 30-day period, capped at 8% of the purchase price.
- Termination: The agreement may be terminated if Closing does not occur by March 15, 2013, or in the event of a material breach.
Investor Verification Checklist
- Verify the status of the stockholder information statement and the 20-day waiting period for Novogen's consent to become effective.
- Confirm the execution of the 1-for-10 reverse stock split and its impact on share counts and warrant exercise prices.
- Review the specific terms of the Governance Agreements (Exhibit 10.2) regarding board composition and committee appointments.
- Monitor the filing of the Initial Registration Statement within 30 days of Closing to avoid liquidated damages.
- Assess the clinical progress of the Pracinostat Phase II study as the primary use of proceeds.